Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic
22 Pages Posted: 14 Apr 2020
More...Abstract
2019-nCoV pandemic has influenced on millions of people’s life across the world, which is caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19). Today, no effective treatment exists; however, scientists are endeavoring to find specific antivirals. The efficacy of several drugs such as remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir are currently undergoing clinical studies in order to discover proper treatment of COVID-19. This article tends to summarize these promising antivirals with potential efficacy against this global challenge. A systematic literature review was performed to screen all of the related papers on COVID-19, using the PubMed, Scopus and Web of Science databases published during five years up to March 22, 2020. We tend to determine the safety and efficacy of remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir. Additionally, we searched Clinicatrial.gov to find ongoing trials. Our search identified seven relevant papers and sixteen ongoing clinical trials. It was clear that there are a few promising therapeutic agents on this horizon. Based on limited evidence in the literature, we suggest that remdesivir treatment, among all of our selected antivirals, accompanied by oxygen inhalations, maintaining fluids, electrolyte and intestinal microbiological modulator balances and nutritional support may be helpful in fighting COVID-19. Based on our systematic results, the use of these antiviral drugs need to be confirmed by ongoing and future clinical trials. The prescription of them in COVID-19 patients should adhere to guidelines to reach better outcome.
Funding Statement: None.
Declaration of Interests: All of authors declare that they have no conflicts of interest to this work.
Keywords: Coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; Pneumonia; Antiviral Therapy; Systematic Review
Suggested Citation: Suggested Citation